

GLAXOSMITHKLINE PLC  
Form 6-K  
July 20, 2016

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending 20 July 2016

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes  No

--

GlaxoSmithKline plc (the 'Company')  
Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name                      Dr S Dexter  
PCA of
- b) Position/status        Dr P J T Vallance  
(President, Pharmaceuticals  
R&D)
- c) Initial notification/  
amendment                Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name                      GlaxoSmithKline plc
- b) LEI                        5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of            Ordinary shares of 25 pence  
The financial                each ('Ordinary Shares')
- a) instrument                ISIN: GB0009252882

- b) Nature of                Acquisition of Ordinary  
The transaction            Shares following the  
re-investment of dividends  
paid to shareholders on 14  
July 2016.

- c) Price(s) and              Price(s)      Volume(s)  
volume(s)                    £16.56      351  
n/a (single transaction)

- d) Aggregated  
information  
Aggregated volume  
Price

- e) Date of the                2016-07-18  
transaction

- f) Place of                    London Stock Exchange  
the transaction              (XLON)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)  
Date: July 20, 2016

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc